Overview of Fosfomin

Quick Facts: Fosfomycin

Property	Description
Active ingredient	Fosfomycin (as tromethamine/trometamol salt)
Form	Powder/granules for oral solution (oral sachet)
Pharmacological class	Antibiotic (Antimicrobial agent)
General purpose	Elimination of bacterial infections
Origin	Synthetic (Phosphonic acid derivative)

What Type of Medicine is Fosfomin (Fosfomycin)?

Fosfomin is a prescription-only medicine containing the active substance Fosfomycin, and it is formally classified as a broad-spectrum antibiotic or antimicrobial agent. Fosfomycin is a unique, synthetic compound that is a phosphonic acid derivative, distinguishing its pharmacological class from common antibiotics like penicillins and macrolides. This distinction is clinically recognized for providing efficacy against a broader spectrum of bacteria.

Composition, Origin, and Form of Fosfomin

The active core is Fosfomycin, typically presented as the salt Fosfomycin tromethamine (or trometamol), which facilitates effective oral absorption. The standard dosage form is a powder for oral solution or granules contained within a single-dose oral sachet formulation, intended for simple oral consumption. While the drug was historically derived from natural sources, it is now produced via a rigorous synthetic process to ensure consistent pharmaceutical quality. This preparation method results in a unique pharmacokinetic profile, often supporting a simplified course of treatment.

What is the General Purpose of This Antibiotic?

The general purpose of Fosfomin is the swift and effective elimination of bacteria causing infection, as it functions as a highly specific bactericidal agent. It achieves this by acting as a targeted cell wall synthesis inhibitor, blocking a crucial early step in the synthesis of the bacterial cell wall. By destroying the structural integrity of the bacterial cell through this unique, early-stage interference, the medicine provides the fundamental benefit of resolving the underlying bacterial infection rapidly. For example, Fosfomycin is typically used to manage acute bacterial infections in appropriate patient groups.

What side effects are possible with Fosfomin?

Possible Side Effects and Safety Information

This section outlines the adverse reactions and safety restrictions associated with oral fosfomycin (Fosfomin/Monurol), based strictly on authoritative government regulatory documents.

Serious Adverse Reactions

The most serious documented safety risks are rare but require immediate attention:

Hypersensitivity: Serious and occasionally fatal reactions, including anaphylaxis and anaphylactic shock, have been reported.
Gastrointestinal: Severe infection of the colon, known as Clostridioides difficile-associated colitis and pseudo-membranous colitis, has been reported and can be life-threatening.

Common Adverse Reactions

Based on clinical data, the most common reported adverse reaction is Diarrhea. Other reported reactions for which the frequency cannot be reliably estimated from available data (Not Known) include vulvovaginitis, headache, dizziness, nausea, dyspepsia, abdominal pain, and vomiting.

Safety Restrictions and Warnings

Contraindication: This medicine must not be used by patients with a known serious hypersensitivity or allergy to fosfomycin or any of its excipients.
Driving and Machinery: Patients should be aware that dizziness has been reported, which may impact their ability to drive or operate machinery.
Population Safety: Use during pregnancy and breastfeeding should occur only if clearly necessary, as the substance is known to cross the placenta and is excreted in low quantities in breast milk. The medicine is indicated for female adolescents but is generally not recommended for children under 12 years due to insufficient safety data in some jurisdictions.

These safety classifications define the documented risks, ranging from common, typically less severe effects to rare, critical events, and establish the conditions under which the medication should be strictly avoided.

Overdose and Emergency Response

Overdose and When to Seek Help

This information summarizes the officially documented manifestations of Fosfomin (Fosfomycin) overdose and the required emergency actions, based strictly on government regulatory labeling.

Element	Official Regulatory Statement
Documented Overdose Presentations	Clinical events observed in overdose include vestibular loss, impaired hearing, metallic taste, and a general decline in taste perception.
Antidote Availability	No specific antidote is known for Fosfomycin.
Management Measure	Treatment must be symptomatic and supportive.

Regulatory Guidance on Emergency Actions

The primary official guidance for overdosage is the mandatory requirement to seek immediate emergency medical attention upon suspicion or occurrence of an overdose event. This action is critical because the drug's overdose profile is characterized by specific documented sensory and vestibular disturbances that necessitate professional observation and immediate supportive care.

Since the official regulatory labeling explicitly states that no specific antidote is known for the drug, the required management strategy focuses entirely on treating the clinical signs experienced by the patient, which falls under the definition of symptomatic and supportive measures. The official documents do not delineate specific dose levels associated with the risk of acute overdose, nor do they detail separate population-based considerations for managing overdosage in groups such as the elderly or those with renal impairment. All interventions are governed by the established scope of symptomatic treatment and medical monitoring.

Therapeutic Uses of Fosfomin

Quick Facts: Primary Therapeutic Domains

Uncomplicated Urinary Tract Infections (UTIs): Used to address acute cystitis in women and adolescent girls.
Complicated Urinary Tract Infections (cUTIs): Indicated for adults, including those with pyelonephritis, when caused by specific susceptible bacteria.
Infection Prevention: Employed as a preventative measure for certain infections in men undergoing transrectal prostate biopsy.

What Fosfomin Treats: Main Uses and Benefits

Fosfomin (which contains the active ingredient fosfomycin) is an antimicrobial agent utilized for addressing bacterial infections, primarily those affecting the urinary tract. The established uses of this medication are based on its ability to help manage the presence of susceptible microorganisms.

The most common therapeutic application of the oral formulation is to assist in the resolution of acute, uncomplicated lower urinary tract infections (cystitis) in female patients, including adolescents. This agent is specifically administered to target common causative bacteria, such as Escherichia coli and Enterococcus faecalis.

For more complex or serious presentations, the intravenous formulation of this drug is reserved for managing complicated urinary tract infections (cUTIs) in adults. These complex cases may encompass pyelonephritis (a type of kidney infection) and are typically addressed only when the infection is caused by bacteria confirmed to be susceptible to the medication, following diagnostic testing.

Furthermore, the oral preparation has an established role in the prophylaxis of infection associated with certain surgical or diagnostic procedures. Specifically, it is utilized to reduce the risk of infection in men who are undergoing a transrectal prostate biopsy.

Regulatory References

EMA therapeutic overview

Eligibility and Restrictions for Use

Fosfomin (fosfomycin) eligibility is strictly defined by regulatory documents, outlining who may and must not use the medicine.

Who is Eligible?

The oral formulation is officially established for use in adult women and adolescent girls aged 12 years and older for the treatment of acute uncomplicated urinary tract infections (UTIs). It is also permitted for men when used specifically as infection prophylaxis associated with transrectal prostate biopsy.

Who Must Not Use Fosfomin? (Contraindications)

Use is absolutely prohibited in the following groups, as stated in regulatory labeling:

Patients with a documented history of hypersensitivity or severe allergic reaction to fosfomycin or any of its excipients.
Patients diagnosed with certain hereditary metabolic disorders, such as fructose intolerance or glucose-galactose malabsorption, due to the excipient content in some formulations.

Age and Condition Restrictions

Population Group	Eligibility Status
Children (≤ 12 years)	Safety and effectiveness are not established; use is not recommended.
Male Patients (for UTI)	Not indicated for treating UTIs in males, as these are typically classified as complicated infections.
Severe Renal Impairment	Not recommended due to the drug's primary reliance on kidney function for excretion.
Pregnancy and Lactation	Permitted only if clearly needed, requiring careful consideration as stated in regulatory labels.
Older Adults	No dosage adjustment is necessary, but caution is advised due to the higher likelihood of reduced organ function.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Fosfomin (Fosfomycin) based on its impact on pharmacokinetics, pharmacodynamics, and administration constraints.

Documented Pharmacokinetic Interactions

Co-administration with Metoclopramide, a motility-increasing agent, officially results in lowered serum concentrations and reduced urinary excretion of Fosfomycin. This pharmacokinetic interference is due to the prokinetic agent accelerating the drug's passage through the gastrointestinal tract, reducing absorption.

Administration Timing Constraints

Food intake is officially documented to delay the absorption of Fosfomycin, leading to a slight decrease in peak plasma levels and urinary concentrations. To optimize drug exposure, it is preferable to take the medicine on an empty stomach or separated by approximately two to three hours from meals.

Pharmacodynamic and Antagonistic Interactions

The use of Fosfomin is officially restricted with Live Bacterial Vaccines (e.g., BCG, Cholera, Typhoid). This restriction is based on documented pharmacodynamic antagonism, where the antibiotic activity may diminish the vaccine's therapeutic effect.
Official labeling notes the potential for Oral Anticoagulants to experience increased activity (alteration of INR) in patients receiving broad-spectrum antibiotics, including Fosfomycin. This necessitates monitoring the anticoagulant status.

Mechanism of Action

Irreversible Blockade of Cell Wall Construction

Fosfomycin functions as a bactericidal agent by disrupting the initial cytoplasmic steps of bacterial cell wall synthesis. Its mechanism requires active delivery into the bacterial cytoplasm, primarily achieved by exploiting the bacteria's own nutrient transporters, such as GlpT and UhpT. Once inside, the drug encounters the essential enzyme UDP-N-acetylglucosamine enolpyruvyl transferase (MurA).

Fosfomycin acts as an irreversible inhibitor, covalently binding to MurA due to its structural mimicry of phosphoenolpyruvate ( PEP). This permanent bond halts the synthesis of peptidoglycan precursors, initiating a destructive cellular cascade. By preventing the assembly of a functional cell wall, the drug eliminates the primary structural support and osmotic protection for the bacterial cell. This loss of integrity results in cellular swelling and physical rupture (lysis), which produces the physiological effect of destruction and elimination of susceptible bacterial cells.

Dosage and Administration Information

How Fosfomin is Used

Fosfomin (fosfomycin 3 g sachet) is administered according to specific, fixed protocols. Use is defined by the medicine's unique single-dose regimen, preparation method, and timing.

Administration Guidelines

Usage Aspect	Instruction
Route of Administration	Oral administration only, via a solution reconstituted from the powder.
Standard Dosing	Uncomplicated Cystitis: A single 3 g dose. Prophylaxis (Prostate Biopsy): Two 3 g doses (pre- and post-procedure).
Course Duration	The treatment course for uncomplicated cystitis is fixed at a single dose. The treatment is generally limited to one dose per episode.

Preparation and Contextual Instructions

To support absorption, the medicine is prepared and taken according to the following instructions:

Preparation: The entire sachet content is dissolved in a glass of water (approximately 90-120 mL or 3-4 ounces). The mixture is consumed immediately after dissolution.
Timing: The dose is taken on an empty stomach (preferably 2 to 3 hours before or after a meal). Taking the dose before bedtime, after emptying the bladder, is a common practice.
Prophylaxis Schedule: For infection prevention in men undergoing transrectal prostate biopsy, the two doses are timed so that the first is taken 3 hours prior to the procedure, and the second 24 hours after the procedure.

Population Restrictions

There are specific constraints on use for certain patient groups:

Pediatric Use: The 3 g oral formulation is not recommended for children under 12 years of age.
Severe Renal Impairment: The oral formulation is contraindicated in patients with severe renal failure (creatinine clearance less than 10 mL/min).

Recent Clinical Evidence

Research evidence / Overview of Studies for Fosfomin

Evidence for Use in Uncomplicated Urinary Tract Infections (UTIs)

The research landscape exploring uncomplicated bladder infections (cystitis) includes short-term Randomized Controlled Trials (RCTs) and Systematic Reviews that was studied for Fosfomin. These studies were studied for how the single-dose regimen compares to multi-day courses of other oral antibiotics in adult women. The main measurements monitored in these trials were outcomes related to physical discomfort (symptoms like pain and urgency) and microbiological resolution (a measured change in the bacteria count).

Systematic reviews describe patterns where the measured rates of outcomes related to physical discomfort and microbiological resolution following Fosfomin administration were associated with the rates observed for the comparator antibiotics used in the trials. Research also monitored the outcomes linked to inflammatory or irritative states, with findings describing patterns observed in the comparison groups. Despite this evidence, long-term effects are not fully established as the follow-up durations were limited.

Evidence for Use in Complicated UTIs and Multi-Drug Resistant Infections

For more serious infections, such as those that are complicated or caused by multi-drug resistant (MDR) bacteria, research exploring these conditions associated with acute or disruptive episodes consists of Observational Cohort Studies and smaller, non-comparative trials. These studies were observed in adults, often including older patients or those with complex health issues.

This research explored the outcomes related to functional imbalance and monitored clinical and microbiological success, especially against pathogens with resistance to many other common drugs. The reported findings often describe patterns observed in the studies conducted during periods of increased symptom activity. Because these reports describe narrow, high-risk patient groups, the findings were mixed and data are still emerging.

Evidence for Use in Infection Prevention for Prostate Biopsy

Research has explored whether Fosfomin was associated with the managing the risk of infectious complications in adult men undergoing a transrectal prostate biopsy (TRUSPB) procedure. Systematic Reviews and RCTs research examined the drug's role in managing the risk of infectious complications and monitored outcomes such as the incidence of fever-related UTIs and overall infection rates during the month following the biopsy.

Findings in this area suggest that the measured rates of infectious complications in the Fosfomin groups data show patterns related to the rates observed with the comparator antibiotics studied for this purpose.

Frequently Asked Questions (FAQ)

Common questions about Fosfomin (FAQ)

Q: How quickly does Fosfomin start working for an infection?

Fosfomin is rapidly absorbed after administration. According to official pharmacokinetic data, the medicine reaches its highest concentration in the urine, where it is intended to target the infection, approximately two to four hours after administration. These therapeutic concentrations are typically maintained for at least 24 hours.

Q: Is it normal to feel nauseous after taking Fosfomin?

Yes, regulatory documents list nausea as a common adverse reaction reported in clinical studies. Other common gastrointestinal effects include diarrhea, abdominal pain, and vomiting. Concerns about severe or persistent nausea should be discussed with a healthcare professional.

Q: Does Fosfomin cause drowsiness or affect driving?

Official safety information reports dizziness as a possible side effect of the medicine. Since this reaction may impact concentration, caution is advised when driving or operating machinery.

Q: Are there any foods or drinks I should avoid while taking Fosfomin?

While regulatory information does not list specific food restrictions to avoid, it does state that food intake delays the medicine's absorption. To optimize the drug's exposure, official guidelines suggest taking the medicine separated from meals, such as on an empty stomach.

Q: Can Fosfomin affect birth control pills?

Regulatory documents do not list oral contraceptives as a specific interaction that contraindicates the use of Fosfomin. However, as a broad-spectrum antibiotic, there is a general, low-risk possibility that it could theoretically affect the gut flora. Any questions regarding specific medication use should be directed to a healthcare provider.

Q: Can I drink alcohol while taking Fosfomin?

Official product information does not list alcohol as a substance that specifically interacts with the medicine and must be avoided. However, alcohol consumption may intensify common side effects of the medication, such as dizziness and nausea.

Q: Can Fosfomin be used during pregnancy?

Official regulatory documents advise that the use of this medicine during pregnancy is only permitted if it is clearly needed. This precaution is advised because the active substance is known to cross the placental barrier. The decision to use this medicine during pregnancy should be made in consultation with a healthcare provider.

Q: What is the typical duration of action for a single dose of Fosfomin?

The medicine is designed as a single-dose regimen. After administration, regulatory pharmacokinetic studies show that therapeutic concentrations of the active substance are maintained in the urine for at least 24 hours. This sustained level is consistent with its intended single-dose use for targeting the bacteria.

Q: Does Fosfomin affect gut flora or cause yeast infections?

Yes, as a broad-spectrum antibiotic, Fosfomin can disrupt the normal balance of micro-organisms. Regulatory information lists diarrhea and Clostridioides difficile-associated colitis (a severe gut infection) as potential adverse reactions. Vulvovaginitis (a vaginal infection) is also listed as a reported reaction.

Q: Why is it important to finish the entire course of Fosfomin?

Even though Fosfomin is a single-dose treatment, it is necessary to consume the entire contents of the sachet of granules to ensure the full intended dose is delivered. With any antibiotic, not taking the full prescribed amount can lead to treatment failure and may contribute to the development of bacterial resistance.

Q: Can Fosfomin be taken by people with diabetes?

Some formulations of the oral powder may contain sugars, such as sucrose, as an excipient (an inactive ingredient). It is recommended that individuals with diabetes discuss their specific medication and its excipient content with a healthcare provider.

Q: Is Fosfomin used for respiratory infections?

The oral formulation of Fosfomin is officially indicated only for the treatment of acute uncomplicated urinary tract infections (UTIs) in eligible patients, and for infection prevention in men undergoing transrectal prostate biopsy. It is not indicated for the treatment of respiratory infections.

Q: How effective is Fosfomin against resistant bacteria?

Studies and official microbiology data indicate that Fosfomin has activity against a broad spectrum of bacteria. Due to its unique mechanism of action, it is effective against some pathogens that may have developed resistance to other common drug classes. This activity contributes to its utility against multi-drug resistant strains.

Q: Why is Fosfomin sometimes considered a last-resort treatment?

Although its primary indication is for uncomplicated UTIs, this medicine’s activity against specific multi-drug resistant (MDR) bacteria means it may be used in complex infections when other antibiotics are ineffective. Its role in complicated infections is noted in research and emerging data for high-risk patients.

Q: What are the main benefits of using Fosfomin over other antibiotics?

The main distinguishing feature of this medicine for acute uncomplicated UTIs is its fixed, simple single-dose regimen. This simplified course of administration, supported by clinical evidence, is a distinguishing feature compared to multi-day antibiotic regimens.

Q: Is there a maximum number of times Fosfomin can be used in a year?

Regulatory documents state that the treatment course for uncomplicated cystitis is fixed at a single dose, and only one dose should be used per infection episode. There is no explicit maximum annual number of doses specified, but repeat use is restricted to treating new, separate infection episodes.

Q: Can Fosfomin be used for skin infections?

Official regulatory documents indicate that the oral formulation of Fosfomin is intended only for the treatment of acute uncomplicated urinary tract infections (UTIs) and for infection prevention in transrectal prostate biopsy. It is not indicated for use in treating skin infections.

Q: What are the signs of a severe allergic reaction to Fosfomin?

Serious and life-threatening hypersensitivity reactions, including anaphylaxis and shock, have been reported. Signs of these reactions typically involve sudden swelling of the face, tongue, or throat, or the sudden onset of difficulty breathing.

How should Fosfomin be stored and disposed of?

Storage and Disposal of Fosfomycin

Official regulatory labeling dictates strict conditions for storing and handling Fosfomycin to maintain its quality.

Storage Requirements

Oral Granules: Store at 25 C (77 F), with excursions permitted up to 30 C. The product must be kept in its original container, protected from moisture and heat.
Intravenous Powder: Store the unopened powder between 15 C and 30 C.
Stability: The reconstituted oral solution must be taken immediately. The diluted IV solution must be used immediately or stored for a maximum of 48 hours under controlled conditions (e.g., protected from light).
Child Safety: All formulations must be kept out of the sight and reach of children.

Disposal

Unused or expired product should not be disposed of in household waste or wastewater. Disposal of the oral product must follow local regulations or be returned to a collection program. Any waste from the intravenous formulation must be disposed of as biohazardous waste.

Fosfomin